Mantle cell lymphoma

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Retrieved on: 
金曜日, 6月 14, 2024
Follicular lymphoma, CD19, Patient, EHA, Hematology, MCL, DLBCL, CRS, European Hematology Association, Euronext, Safety, Galapagos NV, CRS2, Mantle cell lymphoma, Kinetics, CRR, Pharmaceutical industry

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress.

Key Points: 
  • Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress.
  • Galapagos' product candidate GLPG5101 is produced using the company's innovative, decentralized T-cell manufacturing platform.
  • The oral presentation includes updated safety and efficacy data for GLPG5101 in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).
  • 100% of patients in Phase 2 had an ongoing response at data cut-off with median follow-up of 4.2 months.

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

Retrieved on: 
金曜日, 6月 14, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CLL, Methotrexate, PCNSL, Safety, Neoplasm, Mantle cell lymphoma, Aes, NGS, Intolerance, Lenalidomide, CRR, PR, Prognosis, Indolent, MCL, Cytokine release syndrome, ASCT, Pharmacokinetics, Refractory, PD, PB, Chronic lymphocytic leukemia, CRS, European Hematology Association, Efficacy, Rituximab, HKEX, NHL, Lymphoid leukemia, Relapse, EHA, IGHV, IRC, DLBCL, B-cell lymphoma, PFS

Data of InnoCare's (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.

Key Points: 
  • Data of InnoCare's (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.
  • At the doses evaluated, ICP-B02 subcutaneously (SC) demonstrated favorable safety profile and promising efficacy in patients with R/R B-cell NHL.
  • Rapid and deep responses, as well as the convenience of SC formulation, support further clinical development for treatment of B cell NHL.
  • Preliminary Safety and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with ICP-248, a Novel BCL2 Inhibitor (Abstract No.

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

Retrieved on: 
水曜日, 6月 12, 2024
Other Health, Software, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Biotechnology, Other Technology, Health, Patient, MCL, IND, United States patent law, Pancreatic cancer, Mantle cell lymphoma, Sarcoma, NHL, DHL, ATRT, Machine learning, FDA, JPO, Certificate, Artificial intelligence, ODD, Cancer, Pharmaceutical industry

7489966 directed to Lantern Pharma’s drug candidate LP-284 ((+)N-hydroxy-N-(methylacylfulvene)urea).

Key Points: 
  • 7489966 directed to Lantern Pharma’s drug candidate LP-284 ((+)N-hydroxy-N-(methylacylfulvene)urea).
  • The Certificate of Patent entitled “Illudin Analogs, Uses Thereof, and Methods for Synthesizing the Same” covers molecule LP-284, including claims covering the new molecular entity.
  • A Certificate of Patent is issued after JPO examinations have confirmed the merits of a patent request.
  • LP-284 is the second drug candidate from Lantern Pharma to receive such designation from the FDA.

Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting

Retrieved on: 
月曜日, 6月 3, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Cytokine release syndrome, ASCO, Lymphoma, Patient, Annual general meeting, Safety, NHL, Society, Mantle cell lymphoma, BMY, OS, PFS, Lymphoid leukemia, Disease, BTK, Food, Bristol Myers Squibb, MCL, FDA, Infection, CRS, Pharmaceutical industry

The data, presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, underscore Breyanzi as a transformative therapy with demonstrated clinically meaningful outcomes across the broadest array of B-cell malignancies.

Key Points: 
  • The data, presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, underscore Breyanzi as a transformative therapy with demonstrated clinically meaningful outcomes across the broadest array of B-cell malignancies.
  • Please see the Important Safety Information section below, including Boxed WARNINGS for Breyanzi regarding Cytokine Release Syndrome (CRS), Neurologic Toxicities, and Secondary Hematological Malignancies.
  • The 36-month EFS rate with Breyanzi was 45.8% (95% CI: 35.2-56.5) vs. 19.1% (95% CI: 11.0-27.3) for SoC.
  • DOR was not reached with Breyanzi (95% CI: 16.9-NR) and was 9.1 months with SoC (95% CI:.1-NR) (HR:0.603; 95% CI: 0.364.1.000).

City of Hope Researchers to Present Investigational Treatments for Colorectal, Kidney and Blood Cancers at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
Research, Hospitals, Clinical Trials, Telemedicine, Virtual Medicine, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, HLA, Ageing, Blood, Transplant, Medicine, NMDP, Survival, Mantle cell lymphoma, Telephone, Constipation, Lymphoma, Neoplasm, Graft-versus-host disease, Happiness, B cell, Physician, Subduction, Pathology, Anemia, Education, Social work, Clinical trial, Hospital, Comfort, Patient, Student, ASCO, GVHD, Occupational therapy, Environment, City, Haematopoietic system, National Marrow Donor Program, Progression-free survival, Bone marrow, TeleVideo, Fatigue, Abstract, Pharmacy, Quality of life, Nursing

City of Hope has performed over 19,000 transplants, is one of the nation’s leading transplant programs and is at the forefront of using transplants to treat older adults with blood cancers.

Key Points: 
  • City of Hope has performed over 19,000 transplants, is one of the nation’s leading transplant programs and is at the forefront of using transplants to treat older adults with blood cancers.
  • The adult cohorts of this trial recruitment have closed with more than 200 patients in follow-up.
  • Kennedy Geriatric Oncology Award, which honors geriatric oncologists who have demonstrated outstanding leadership and achievement in the field of geriatric oncology.
  • Presenter: Richard T. Lee , M.D., City of Hope clinical professor, Supportive and Integrative Medicine Program; Cherng Family Director's Chair for the Center for Integrative Oncology
    Presenter: Daniel Schmolze , M.D., City of Hope associate clinical professor, Department of Pathology

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
火曜日, 5月 14, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Mantle cell lymphoma, Holocene, Renal cell carcinoma, MCL, FDA, Safety, Protocol, Cancer, NHL, Research and development, Administration, Bone marrow, Lupus nephritis, Pharmaceutical industry

The Company plans to commence a Phase 1 clinical trial to assess the safety and efficacy of ADI-001 in lupus nephritis in the second quarter of 2024.

Key Points: 
  • The Company plans to commence a Phase 1 clinical trial to assess the safety and efficacy of ADI-001 in lupus nephritis in the second quarter of 2024.
  • Preliminary data from the study are anticipated during the fourth quarter of 2024 or first quarter of 2025, depending on patient enrollment and study site activation.
  • Based on ADI-270’s promising profile in preclinical studies to date, Adicet expects to submit an IND for ADI-270 in renal cell carcinoma in the second quarter of 2024.
  • Financial Results for First Quarter 2024:
    Research and Development (R&D) Expenses: R&D expenses were $23.9 million for the three months ended March 31, 2024, compared to $26.8 million during the same period in 2023.

Verismo Therapeutics Receives IND Clearance from the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL

Retrieved on: 
火曜日, 5月 14, 2024
B cell, Patient, Verismo, Follicular lymphoma, Food, MCL, NK, CD19, FDA, B-cell lymphoma, Therapy, Trial of the century, Malignancy, Safety, Mantle cell lymphoma, Bone marrow, NHL, DLBCL, Pharmaceutical industry

PHILADELPHIA, May 14, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has received a notification from the US Food and Drug Administration (FDA) that the Phase 1 clinical trial of SynKIR™-310 for the investigation of NHL may proceed.

Key Points: 
  • Commercially approved CAR T cell therapies have shown impressive high initial response rates in blood cancers.
  • There are currently very limited treatment options for patients with r/r DLBCL who relapse following treatment with commercial CAR T cell therapies.
  • "Verismo Therapeutics is uniquely positioned with SynKIR™-310 to address the significant challenges in treating relapsed/refractory B-cell NHL.
  • This includes cases where patients have relapsed after receiving approved CAR T therapies," stated Dr. Laura Johnson, Chief Scientific Officer of Verismo Therapeutics.

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Retrieved on: 
木曜日, 5月 9, 2024
Stem Cells, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Mantle cell lymphoma, Cancer, International Society, Investment, Cell, Phenotype, Safety, Risk, Pharmacokinetics, Poster, Lymphoproliferative disorders, Depreciation, Cytokine, Partnership, Lymphoma, Biologics license application, ATRA, Follicular lymphoma, CD19, ASH, Epstein–Barr virus, Patient, NHL, LD, Toxicity, BLA, Memory, Workforce, EBV, Biomarker, SLE, Tabelecleucel, Pharmaceutical industry

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.
  • “This is anticipated to provide multiple near-term clinical milestones for ATA3219, including initial non-Hodgkin’s lymphoma data expected in the fourth quarter 2024, and initial lupus nephritis data in the first half of 2025, with plans to expand into a new SLE cohort without lymphodepletion.
  • Subjects will receive lymphodepletion treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
木曜日, 5月 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
木曜日, 5月 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.